{
    "clinical_study": {
        "@rank": "8215", 
        "acronym": "Hesperidin", 
        "arm_group": [
            {
                "arm_group_label": "Hesperidin and Calcilock", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will consume 4 cookies containing Hesperidin and Calcilock."
            }, 
            {
                "arm_group_label": "Hesperidin", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will consume 4 cookies containing Hesperidin, 552mg, daily"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will consume 4 cookies daily without Hesperidin or Calcilock."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this clinical trial is to test hesperidin with and without\n      CALCILOCK\u00ae for bone resorption suppressing effect in postmenopausal women. The secondary\n      objective is the comparison between 41Ca technology and classical biomarker to evaluate bone\n      resorption."
        }, 
        "brief_title": "Hesperidin and Bone Health in Postmenopausal Women", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Osteoporosis, Postmenopausal", 
        "condition_browse": {
            "mesh_term": [
                "Osteoporosis", 
                "Osteoporosis, Postmenopausal"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects will participate in four phases of the study: Baseline of 50 days and three\n      intervention phases which include 50 days receiving product followed by 50 days of recovery.\n      The total duration of the study will be 350 days.  If participant has not been previously\n      labeled with 41Ca, a 150 day period is added to the study.\n\n      Hesperidin (552mg) and Calcilock\u00ae (amount per day: Calcium: 684 mg; Phosphorus: 282mg;\n      Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28\u00b5g; Vitamin D: 1.86\u00b5g) will\n      be administered in the form of cookies (biscuit)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women at least 4 years postmenopausal\n\n        Exclusion Criteria:\n\n          -  Medications affecting bone resorption"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01881204", 
            "org_study_id": "10.21.NRC"
        }, 
        "intervention": [
            {
                "arm_group_label": "Hesperidin and Calcilock", 
                "description": "Hesperidin (552mg) and Calcilock\u00ae (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28\u00b5g; Vitamin D: 1.86\u00b5g) will be administered in the form of cookies (biscuit).", 
                "intervention_name": "Hesperidin and Calcilock", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Hesperidin", 
                "description": "Hesperidin (552mg) will be administered in the form of cookies (biscuit).", 
                "intervention_name": "Hesperidin", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Cookies without Hesperidin or Calcilock added.", 
                "intervention_name": "Control", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hesperidin", 
            "Osteoporosis", 
            "Bone Loss"
        ], 
        "lastchanged_date": "June 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "West Lafayette", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "47907"
                }, 
                "name": "Purdue University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Hesperidin and Bone Health in Postmenopausal Women", 
        "overall_official": [
            {
                "affiliation": "Purdue University", 
                "last_name": "Connie M Weaver, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Purdue University", 
                "last_name": "Berdine R Martin, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Elimination of 41Calcium in Urine.", 
            "safety_issue": "No", 
            "time_frame": "50 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01881204"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Purdue University", 
            "investigator_full_name": "Berdine Martin", 
            "investigator_title": "Research Scientist, Nutrition Science", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Purdue University", 
        "sponsors": {
            "collaborator": {
                "agency": "Nestec Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Purdue University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}